The administration of a humanized anti-TLR2 mAb, tomaralimab, in human tumor xenograft models of gastric and pancreatic cancers markedly inhibited the growth of tumors exhibiting high TLR2 expression and/or activation. The gene discussed is TLR2; the disease is pancreatic neoplasm.